Saharkhiz Shaghayegh, Zarepour Atefeh, Zarrabi Ali
Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan 81746-73441, Iran.
Department of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University, Istanbul 34396, Türkiye.
Bioengineering (Basel). 2023 Oct 2;10(10):1159. doi: 10.3390/bioengineering10101159.
Cancer remains an enduring challenge in modern society, prompting relentless pursuits to confront its complexities. However, resistance often emerges against conventional treatments, driven by their inherent limitations such as adverse effects and limited solubility. Herein, we spotlight a remarkable solution; a niosomal platform engineered to tandemly ferry two potent agents, doxorubicin (DOX) and curcumin (CUR). Notably, we delve into the pivotal role of PEGylation, unraveling its impact on therapeutic efficacy. These niosomes consist of Span 60, Tween 60, and cholesterol with a molar ratio of 5:2:3, which were prepared via a thin film hydration method. The physicochemical characterization of particles was performed using DLS, zeta potential measurement, SEM, and FTIR analysis. In addition, their encapsulation efficiency and release profile were determined using the HPLC method. Finally, their cytotoxicity and biocompatibility effects were checked by performing an MTT assay test on the MCF7 and L929 cell lines. The obtained results confirmed the successful fabrication of co-loaded niosomal structures with and without PEG coating. The fabricated nanoparticles had sizes in the range of 100 to 200 nm with a surface charge of about -18 mV for particles without PEG coating and -40 mV for coated particles. Notably, DOX encapsulation efficiency leaps from 20% to 62% in the transition from uncoated to coated, while CUR exhibits an impressive surge from 80% to 95%. The drug release was more controlled and slower in the coated sample. Finally, the MTT results confirmed the biocompatibility and synergistic effect of the simultaneous use of two drugs on cancer cells in the PEGylated niosomal particle. Based on the results, PEGylated niosomal particles can be considered adept vehicles for the simultaneous delivery of different chemotherapy cargoes with synergic interaction to overcome cancer.
癌症在现代社会中仍然是一个持久的挑战，促使人们不懈地努力应对其复杂性。然而，由于传统治疗方法存在诸如副作用和溶解度有限等固有局限性，耐药性往往会出现。在此，我们重点介绍一种卓越的解决方案；一种经工程设计的囊泡平台，可串联运送两种强效药物，即阿霉素（DOX）和姜黄素（CUR）。值得注意的是，我们深入探讨了聚乙二醇化的关键作用，揭示了其对治疗效果的影响。这些囊泡由司盘60、吐温60和胆固醇按5:2:3的摩尔比组成，通过薄膜水化法制备。使用动态光散射（DLS）、zeta电位测量、扫描电子显微镜（SEM）和傅里叶变换红外光谱（FTIR）分析对颗粒进行物理化学表征。此外，使用高效液相色谱（HPLC）方法测定它们的包封率和释放曲线。最后，通过对MCF7和L929细胞系进行MTT试验来检查它们的细胞毒性和生物相容性效应。获得的结果证实了成功制备了有和没有聚乙二醇涂层的共负载囊泡结构。制备的纳米颗粒尺寸在100至200纳米范围内，没有聚乙二醇涂层的颗粒表面电荷约为 -18 mV，有涂层的颗粒表面电荷为 -40 mV。值得注意的是，在从未涂层到有涂层的转变过程中，阿霉素的包封率从20%跃升至62%，而姜黄素则从80%大幅飙升至95%。在有涂层的样品中，药物释放更受控制且更缓慢。最后，MTT结果证实了聚乙二醇化囊泡颗粒中同时使用两种药物对癌细胞的生物相容性和协同效应。基于这些结果，聚乙二醇化囊泡颗粒可被视为用于同时递送具有协同相互作用的不同化疗药物以克服癌症的合适载体。
